Kesimpta

The solution is clear to slightly opalescent, and colourless to slightly brownish-yellow.
Each pre-filled pen contains 20 mg ofatumumab in 0.4 ml solution (50 mg/ml).
Ofatumumab is a fully human monoclonal antibody produced in a murine cell line (NS0) by recombinant DNA technology.
Excipients/Inactive Ingredients: L-arginine, Sodium acetate trihydrate, Sodium chloride, Polysorbate 80, Disodium edetate dihydrate, Hydrochloric acid (for pH adjustment), Water for injections.

Pharmacotherapeutic group: immunosuppressants, monoclonal antibodies. ATC code: L04AG12.
Pharmacology: Pharmacodynamics: Mechanism of action: Ofatumumab is a fully human anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody with a theoretical average molecular weight of 145kDa. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage. The CD20 molecule is also expressed on a small fraction of activated T cells. A subcutaneous route of administration of ofatumumab and subsequent release/absorption from the tissue allows a gradual interaction with B cells.
The binding of ofatumumab to CD20 induces lysis of CD20+ B cells primarily through complement-dependent cytotoxicity (CDC) and, to a lesser extent, through antibody-dependent cell-mediated cytotoxicity (ADCC). Ofatumumab has also been shown to induce cell lysis in both high and low CD20-expressing cells. CD20-expressing T cells are also depleted by ofatumumab.
Pharmacodynamic effects: B-cell depletion: In the RMS clinical studies using ofatumumab 20 mg every 4 weeks, after an initial dose regimen of 20 mg on days 1, 7, and 14, administration resulted in a rapid and sustained reduction of B cells to below LLN (defined as 40 cells/μl) as early as two weeks after treatment initiation. Before initiation of the maintenance phase starting at week 4, total B-cell levels of <10 cells/μl were reached in 94% of patients, increasing to 98% of patients at week 12, and were sustained for as long as 120 weeks (i.e. while on study treatment).
B-cell repletion: Data from RMS phase III clinical studies indicate a median time to B-cell recovery to LLN or baseline value of 24.6 weeks post treatment discontinuation. PK-B cell modelling and simulation for B-cell repletion corroborate this data, predicting median time to B-cell recovery to LLN of 23 weeks post treatment discontinuation.
Immunogenicity: In RMS phase III studies, the overall incidence of treatment-induced anti-drug antibodies (ADAs) was 0.2% (2 of 914) in ofatumumab-treated patients and no patients with treatment enhancing or neutralising ADA were identified. The impact of positive ADA titers on PK, safety profile or B-cell kinetics cannot be assessed given the low incidence of ADA associated with ofatumumab.
Clinical efficacy and safety: The efficacy and safety of ofatumumab were evaluated in two randomised, double-blind, active-controlled phase III pivotal studies of identical design (Study 1 [ASCLEPIOS I] and Study 2 [ASCLEPIOS II]) in patients with relapsing forms of MS (RMS) aged 18 to 55 years, a disability status at screening with an Expanded Disability Status Scale (EDSS) score from 0 to 5.5, and who had experienced at least one documented relapse during the previous year or two relapses during the previous two years or positive gadolinium (Gd)-enhancing MRI scan during the previous year. Both newly diagnosed patients and patients switching from their current treatment were enrolled.
In the two studies, 927 and 955 patients with RMS, respectively, were randomised 1:1 to receive either ofatumumab 20 mg subcutaneous injections every 4 weeks starting at week 4 after an initial dosing regimen of three weekly 20 mg doses in the first 14 days (on days 1, 7 and 14) or teriflunomide 14 mg capsules orally once daily. Patients also received matching placebo corresponding to the other treatment arm to ensure blinding (double-dummy design).
The treatment duration for individual patients was variable based on when the end of study criteria were met. Across both studies, the median treatment duration was 85 weeks, 33.0% of patients in the ofatumumab group vs 23.2% of patients in the teriflunomide group were treated more than 96 weeks.
Demographics and baseline characteristics were well-balanced across treatment arms and both studies (see Table 1). Mean age was 38 years, mean disease duration was 8.2 years since onset of first symptom, and mean EDSS score was 2.9; 40% of patients had not been previously treated with a disease-modifying therapy (DMT) and 40% had gadolinium (Gd)-enhancing T1 lesions on their baseline MRI scan.
The primary efficacy endpoint of both studies was the annualised rate of confirmed relapses (ARR) based on EDSS. Key secondary efficacy endpoints included the time to disability worsening on EDSS (confirmed at 3 months and 6 months), defined as an increase in EDSS of ≥1.5, ≥1, or ≥0.5 in patients with a baseline EDSS of 0, 1 to 5, or ≥5.5, respectively. Further key secondary endpoints included the number of Gd-enhancing T1 lesions per MRI scan and the annualised rate of new or enlarging T2 lesions. Disability-related key secondary endpoints were evaluated in a meta-analysis of combined data from ASCLEPIOS Study 1 and Study 2, as defined in the study protocols.

Click on icon to see table/diagram/image

The efficacy results for both studies are summarised in Table 2 and figure.
In both phase III studies, ofatumumab compared to teriflunomide demonstrated a significant reduction in the annualised relapse rate of 50.5% and 58.4%, respectively.
The pre-specified meta-analysis of combined data showed that ofatumumab compared to teriflunomide significantly reduced the risk of 3-month confirmed disability progression (CDP) by 34.3% and the risk of 6-month CDP by 32.4% (see figure).
Ofatumumab compared to teriflunomide significantly reduced the number of Gd-enhancing T1 lesions by 95.9% and the rate of new or enlarging T2 lesions by 83.5% (values represent mean reductions for the combined studies).
A similar effect of ofatumumab on the key efficacy results compared to teriflunomide was observed across the two phase III studies in exploratory subgroups defined by sex, age, body weight, prior non-steroid MS therapy, and baseline disability and disease activity. (See Table 2 and figure.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

In the phase III studies, the proportion of patients with adverse events (AEs) (83.6% vs 84.2%) and the AEs leading to discontinuation (5.7% vs 5.2%) were similar in the ofatumumab and teriflunomide groups.
Paediatric population: The European Medicines Agency has deferred the obligation to submit the results of studies with Kesimpta in one or more subsets of the paediatric population in the treatment of multiple sclerosis (see Dosage & Administration for information on paediatric use).
Pharmacokinetics: Absorption: After subcutaneous administration, ofatumumab has a prolonged release/absorption profile (T_max of 4.3 days) and is predominantly absorbed via the lymphatic system.
A monthly subcutaneous dose of 20 mg leads to a mean AUC_tau of 483 μg*h/ml and a mean C_max of 1.43 μg/ml at steady state.
Distribution: The volume of distribution at steady state was estimated to be 5.42 litres following repeated subcutaneous administration of ofatumumab at a dose of 20 mg.
Biotransformation: Ofatumumab is a protein for which the expected metabolic pathway is degradation to small peptides and amino acids by ubiquitous proteolytic enzymes.
Elimination: Ofatumumab is eliminated in two ways: a target-mediated route that is related to binding to B cells and a target-independent route mediated by non-specific endocytosis followed by intracellular catabolism, as with other IgG molecules. B cells present at baseline result in a greater component of target-mediated clearance of ofatumumab at the start of therapy. Ofatumumab dosing leads to potent depletion of B cells resulting in reduced overall clearance.
The half-life at steady state was estimated to be approximately 16 days following repeated subcutaneous administration of ofatumumab at a dose of 20 mg.
Linearity/non-linearity: Ofatumumab had non-linear pharmacokinetics related to its decreasing clearance over time.
Special populations: Adults over 55 years old: There are no dedicated pharmacokinetic studies of ofatumumab in patients over 55 years old due to limited clinical experience (see Dosage & Administration).
Paediatric population: No studies have been conducted to investigate the pharmacokinetics of ofatumumab in paediatric patients below the age of 18 years.
Gender: Gender had a modest (12%) effect on ofatumumab central volume of distribution in a cross-study population analysis, with higher C_max and AUC values observed in female patients (48% of the patients in this analysis were male and 52% were female); these effects are not considered clinically relevant, and no dose adjustment is recommended.
Body weight: Based on the results of a cross-study population analysis, body weight was identified as a covariate of exposure (C_max and AUC) to ofatumumab in RMS subjects. However, body weight did not affect safety and efficacy measures evaluated in the clinical studies; therefore, dose adjustment is not required.
Renal impairment: No specific studies of ofatumumab in patients with renal impairment have been performed.
Patients with mild renal impairment were included in clinical studies. There is no experience in patients with moderate and severe renal impairment. However, as ofatumumab is not excreted via urine, it is not expected that patients with renal impairment require dose modification.
Hepatic impairment: No studies of ofatumumab in patients with hepatic impairment have been performed.
Since hepatic metabolism of monoclonal antibodies such as ofatumumab is negligible, hepatic impairment is not expected to impact its pharmacokinetics. Therefore, it is not expected that patients with hepatic impairment require dose modification.
Toxicology: Preclinical safety data: Non-clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity including safety pharmacology endpoints.
Neither carcinogenicity nor mutagenicity studies have been conducted with ofatumumab. As an antibody, ofatumumab is not expected to interact directly with DNA.
The embryo-foetal development (EFD) and the enhanced pre/post-natal development (ePPND) studies in monkeys showed that exposure to ofatumumab given intravenously during gestation caused no maternal toxicity, no teratogenicity, and no adverse effects on embryo-foetal and pre/post-natal development.
In these studies, ofatumumab was detected in the blood of the foetuses and infants, confirming placental transfer and foetal exposure to ofatumumab persisting post-natally (long half-life of the monoclonal antibody). Exposure to ofatumumab during gestation led to the expected depletion of CD20+ B cells in maternal animals and their foetuses and infants, along with a reduced spleen weight (without histological correlate) in foetuses and a reduced humoral immune response to keyhole limpet haemocyanin (KLH) in infants at high doses. All these changes were reversible during the 6-month post-natal period. In infants, early post-natal mortality was observed at a dose 160 times higher than the therapeutic dose (on AUC basis) and was likely due to potential infections secondary to immunomodulation. The NOAEL related to the pharmacological activity of ofatumumab in infants of the ePPND study leads to an AUC-based safety margin of at least 22-fold when maternal exposure at the NOAEL is compared with human exposure at the therapeutic dose of 20 mg monthly.
In a dedicated monkey fertility study, male and female fertility endpoints were unaffected.

Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see Pharmacology: Pharmacodynamics under Actions).

Treatment should be initiated by a physician experienced in the management of neurological conditions.
Posology: The recommended dose is 20 mg ofatumumab administered by subcutaneous injection with: initial dosing at weeks 0, 1 and 2, followed by subsequent monthly dosing, starting at week 4.
Missed doses: If an injection is missed, it should be administered as soon as possible without waiting until the next scheduled dose. Subsequent doses should be administered at the recommended intervals.
Special populations: Adults over 55 years old: No studies have been performed in MS patients over 55 years old. Based on the limited data available, no dose adjustment is considered necessary in patients over 55 years old (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: Patients with renal impairment are not expected to require dose modification (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: Patients with hepatic impairment are not expected to require dose modification (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of Kesimpta in children aged 0 to 18 years have not yet been established. No data are available.
Method of administration: This medicinal product is intended for patient self-administration by subcutaneous injection.
The usual sites for subcutaneous injections are the abdomen, the thigh and the upper outer arm.
The first injection should be performed under the guidance of a healthcare professional (see Precautions).
Comprehensive instructions for administration are provided in the package leaflet.

Doses up to 700 mg have been administered in clinical studies with MS patients without dose-limiting toxicity. In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted as necessary.
Ofatumumab has been previously used in chronic lymphocytic leukaemia (CLL) indications, at doses up to 2,000 mg administered intravenously via infusion. Ofatumumab administered via subcutaneous injection has not been assessed and is not approved for these indications, and must not be used for the treatment of oncology indications.

Hypersensitivity to the active substance or to any of the excipients listed in Description.
Patients in a severely immunocompromised state (see Precautions).
Severe active infection until resolution (see Precautions).
Known active malignancy.

Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Injection-related reactions: Patients should be informed that systemic injection-related reactions (SIRRs) could occur, generally within 24 hours and predominantly following the first injection (see Adverse Reactions). Symptoms most frequently observed in RMS clinical studies include fever, headache, myalgia, chills, fatigue, nausea and vomiting and were predominantly (99.8%) mild to moderate in severity. There were no life-threatening SIRRs reported in RMS clinical studies (see Adverse Reactions).
Additional SIRRs reported in the post-marketing setting include rash, urticaria, dyspnoea and angioedema (e.g. tongue, pharyngeal or laryngeal swelling), and rare cases which were reported as anaphylaxis. While there were some cases which were serious and resulted in discontinuation of ofatumumab treatment, there were also serious cases where patients were able to continue ofatumumab treatment without further incidents.
Some SIRR symptoms may be clinically indistinguishable from Type 1 acute hypersensitivity reactions (IgE-mediated). A hypersensitivity reaction may present during any injection, although typically would not present with the first injection. For subsequent injections, more severe symptoms than previously experienced, or new severe symptoms, should prompt consideration of a potential hypersensitivity reaction. Patients with known IgE-mediated hypersensitivity to ofatumumab must not be treated with ofatumumab (see Contraindications).
Only limited benefit of premedication with steroids was seen in RMS clinical studies. Injection-related reactions can be managed with symptomatic treatment, should they occur. Therefore, use of premedication is not required.
Injection site reaction (local) symptoms observed in clinical studies included erythema, swelling, itching and pain (see Adverse Reactions).
The first injection should be performed under the guidance of an appropriately trained healthcare professional (see Dosage & Administration).
Infections: It is recommended to evaluate the patient's immune status prior to initiating therapy.
Based on its mode of action and available clinical experience, ofatumumab has the potential for an increased risk of infections (see Adverse Reactions).
Administration should be delayed in patients with an active infection until the infection is resolved.
Ofatumumab must not be given to patients in a severely immunocompromised state (e.g. significant neutropenia or lymphopenia).
Progressive multifocal leukoencephalopathy: Since John Cunningham (JC) virus infection resulting in progressive multifocal leukoencephalopathy (PML) has been observed in patients treated with anti-CD20 antibodies, other MS therapies, and ofatumumab at substantially higher doses in oncology indications, physicians should be vigilant for medical history of PML and for any clinical symptoms or MRI findings that may be suggestive of PML. If PML is suspected, treatment with ofatumumab should be suspended until PML has been excluded.
Hepatitis B virus reactivation: Hepatitis B reactivation has occurred in patients treated with anti-CD20 antibodies, which in some cases resulted in fulminant hepatitis, hepatic failure and death.
Patients with active hepatitis B disease should not be treated with ofatumumab. HBV screening should be performed in all patients before initiation of treatment. As a minimum, screening should include hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) testing. These can be complemented with other appropriate markers as per local guidelines. Patients with positive hepatitis B serology (either HBsAg or HBcAb) should consult a liver disease expert before the start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation.
Treatment of severely immunocompromised patients: Patients in a severely immunocompromised state must not be treated until the condition resolves (see Contraindications).
It is not recommended to use other immunosuppressants concomitantly with ofatumumab except corticosteroids for symptomatic treatment of relapses.
Vaccinations: All immunisations should be administered according to immunisation guidelines at least 4 weeks prior to initiation of ofatumumab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ofatumumab for inactivated vaccines.
Ofatumumab may interfere with the effectiveness of inactivated vaccines.
The safety of immunisation with live or live-attenuated vaccines following ofatumumab therapy has not been studied. Vaccination with live or live-attenuated vaccines is not recommended during treatment and after discontinuation until B-cell repletion (see Interactions). The median time to B-cell recovery to the lower limit of normal (LLN, defined as 40 cells/μl) or baseline value is 24.6 weeks post treatment discontinuation based on data from phase III studies (see Pharmacology: Pharmacodynamics under Actions).
Vaccination of infants born to mothers treated with ofatumumab during pregnancy: In infants of mothers treated with ofatumumab during pregnancy, live or live-attenuated vaccines should not be administered before the recovery of B-cell counts has been confirmed. Depletion of B cells in these infants may increase the risks from live or live-attenuated vaccines.
Inactivated vaccines may be administered as indicated prior to recovery from B-cell depletion, however assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted (see Use in Pregnancy & Lactation).
Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
Effects on ability to drive and use machines: Kesimpta has no or negligible influence on the ability to drive and use machines.

Women of childbearing potential: Women of childbearing potential should use effective contraception (methods that result in less than 1% pregnancy rates) while receiving Kesimpta and for 6 months after the last administration of Kesimpta.
Pregnancy: There is a limited amount of data from the use of ofatumumab in pregnant women. Ofatumumab may cross the placenta and cause foetal B-cell depletion based on findings from animal studies (see Pharmacology: Toxicology: Preclinical safety data under Actions). No teratogenicity was observed after intravenous administration of ofatumumab to pregnant monkeys during organogenesis.
Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. The potential duration of B-cell depletion in infants exposed to ofatumumab in utero, and the impact of B-cell depletion on the safety and effectiveness of vaccines, are unknown (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Treatment with ofatumumab should be avoided during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus.
To help determine the effects of ofatumumab in pregnant women, healthcare professionals are encouraged to report all pregnancy cases and complications that happen during treatment or within 6 months after the last dose of ofatumumab to the local representative of the marketing authorisation holder by sending email to safety.hk@novartis.com in order to allow monitoring of these patients through the PRegnancy outcomes Intensive Monitoring programme (PRIM). In addition, all adverse pregnancy events should be reported.
Lactation: The use of ofatumumab in women during lactation has not been studied. It is unknown whether ofatumumab is excreted in human milk. In humans, excretion of IgG antibodies in milk occurs during the first few days after birth, which is decreasing to low concentrations soon afterwards. Consequently, a risk to the breast-fed child cannot be excluded during this short period. Afterwards, ofatumumab could be used during breast-feeding if clinically needed. However, if the patient was treated with ofatumumab up to the last few months of pregnancy, breast-feeding can be started immediately after birth.
Fertility: There are no data on the effect of ofatumumab on human fertility.
Non-clinical data did not indicate potential hazards for humans based on male and female fertility parameters assessed in monkeys.

Summary of the safety profile: The most important and frequently reported adverse reactions are upper respiratory tract infections (39.4%), systemic injection-related reactions (20.6%), injection-site reactions (10.9%) and urinary tract infections (11.9%) (see Precautions and Description of selected adverse reactions as follows for further details).
Tabulated list of adverse reactions: Adverse reactions that have been reported in association with the use of ofatumumab in pivotal RMS clinical studies and from post-marketing experience are listed by MedDRA system organ class in Table 3. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). (See Table 3.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Infections: In the RMS phase III clinical studies, the overall rate of infections and serious infections in patients treated with ofatumumab was similar to patients who were treated with teriflunomide (51.6% vs 52.7%, and 2.5% vs 1.8%, respectively). Two patients (0.2%) discontinued and 11 patients (1.2%) temporarily interrupted study treatment due to a serious infection.
Upper respiratory tract infections: In these studies, 39.4% of ofatumumab-treated patients experienced upper respiratory tract infections compared to 37.8% of teriflunomide-treated patients. The infections were predominantly mild to moderate and mostly consisted of nasopharyngitis, upper respiratory tract infection and influenza.
Injection-related reactions: In the RMS phase III clinical studies, injection-related reactions (systemic) were reported in 20.6% of patients treated with ofatumumab.
The incidence of injection-related reactions was highest with the first injection (14.4%), decreasing significantly with subsequent injections (4.4% with second, <3% from third injection). Injection-related reactions were mostly (99.8%) mild to moderate in severity. Two (0.2%) ofatumumab-treated MS patients reported serious injection-related reactions but not life-threatening. The most frequently reported symptoms (≥2%) included fever, headache, myalgia, chills and fatigue. Additional reported symptoms included nausea (1.7%) and vomiting (0.6%).
Injection-site reactions: In the RMS phase III clinical studies, injection-site reactions (local) were reported in 10.9% of patients treated with ofatumumab.
Local reactions at the administration site were very common. Injection-site reactions were all mild to moderate in severity and non-serious in nature. The most frequently reported symptoms (≥2%) included erythema, pain, itching and swelling.
Laboratory abnormalities: Immunoglobulins: During the course of the RMS phase III clinical studies, decrease in mean value of immunoglobulin M (IgM) (30.9% decrease after 48 weeks and 38.8% decrease after 96 weeks) was observed and no association with risk of infections, including serious infections, was shown.
In 14.3% of patients, treatment with ofatumumab resulted in a decrease in IgM that reached a value below 0.34 g/l.
Ofatumumab was associated with a transient decrease of 4.3% in mean immunoglobulin G (IgG) levels after 48 weeks of treatment but an increase of 2.2% after 96 weeks.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.

No interaction studies have been performed, as no interactions are expected via cytochrome P450 enzymes, other metabolising enzymes or transporters.
Vaccinations: The safety of and the ability to generate a primary or anamnestic (recall) response to immunisation with live, live-attenuated or inactivated vaccines during ofatumumab treatment has not been investigated. The response to vaccination could be impaired when B cells are depleted. It is recommended that patients complete immunisations prior to the start of ofatumumab therapy (see Precautions).
Other immunosuppressive or immune-modulating therapies: The risk of additive immune system effects should be considered when co-administering immunosuppressive therapies with ofatumumab.
When initiating ofatumumab after other immunosuppressive therapies with prolonged immune effects or initiating other immunosuppressive therapies with prolonged immune effects after ofatumumab, the duration and mode of action of these medicinal products should be taken into account because of potential additive immunosuppressive effects (see Pharmacology: Pharmacodynamics under Actions).

Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Special precautions for disposal and other handling: Instructions for handling of the pre-filled pen: Before injection, the pre-filled pen should be taken out of the refrigerator for about 15 to 30 minutes to allow it to reach room temperature. The pre-filled pen should be kept in the original carton until ready to use, and the cap should not be removed until just before the injection is performed. Prior to use, the solution should be inspected visually by looking through the viewing window. The pre-filled pen should not be used if the liquid contains visible particles or is cloudy.
Comprehensive instructions for administration are given in the package leaflet.
Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Store in a refrigerator (2°C-8°C). Do not freeze.
If necessary, Kesimpta may be stored unrefrigerated for a single period of up to 7 days at room temperature (not above 30°C). If not used during this period, Kesimpta can then be returned to the refrigerator for a maximum of 7 days.
Keep the pre-filled pen in the outer carton in order to protect from light.

Immunosuppressants

L04AG12 - ofatumumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.

P₁S₁S₃